866-997-4948(US-Canada Toll Free)

Herceptin (Gastric Cancer) -Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Cancer

No. of Pages : 32 Pages


GlobalDatas pharmaceuticals report, Herceptin (Gastric Cancer)-Analysis and Forecasts to 2020 provides Herceptin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Herceptin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Herceptin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2010-2020 for Herceptin in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3

2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 6

3 Gastric Cancer Disease Market : Market Characteristics 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecasts and CAGR 7
3.3 Drivers for the Gastric Cancer Disease Market 7
3.3.1 High Prevalence 8
3.3.2 High Incidence 8
3.3.3 Low Initial Diagnosis Rate 9
3.3.4 High Mortality Rate 9

4 Tumor Node Metastases (TNM) Classification of Gastric Cancer 10

5 Herceptin 13

5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
5.4 Approval History of Herceptin 15
5.5 Sales Drivers 16
5.5.1 Gastric Cancer Market 16
5.5.2 New Era of Targeted Therapy 16
5.5.3 Increased Survival Rate 16
5.5.4 Low Competition 16
5.6 Drug Evaluation 17
5.6.1 Drug Risk Benefit Score 17
5.6.2 Competition 18
5.7 Sales forecast 18
5.7.1 Target patient Pool of Herceptin 18
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 20
5.7.5 Sales Projections of Herceptin 20

6 Gastric Cancer Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abberiviations 31
6.3 Research Methodology 31
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 31
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 32
6.5 Disclaimer 32
6.6 Sources 32

List of Table


Table 1: Gastric Cancer Incidence and Mortality,20082030 5
Table 2: Gastric Cancer, Global, Market Forecast ($bn), 2002 7
Table 3: Herceptin as a Combination Therapy 13
Table 4: Herceptin as a monotherapy 13
Table 5: Comparison of Herceptin+ Anthracycline with Anthracycline alone 14
Table 6: Comparison of Herceptin+ Paclitaxel with Paclitaxel alone 15
Table 7: Comparison of Herceptin+ Docetaxel with Docetaxel alone 15
Table 8: Results of Herceptin as a monotherapy 15
Table 9: Results of TAnDEM study 15
Table 10: Approval and Expiry of Herceptin in Different Countries 16
Table 11: Drug Risk Benefit Score 17
Table 12: Annual Cost of Therapy 20
Table 13: Gastric Cancer, Global, Sales Forecasts, 20102020 21
Table 14: Gastric Cancer,The US, Sales Forecasts ($m), 20112020 22
Table 15: Gastric Cancer, The UK, Estimated Sales of Herceptin ($m), 20102020 23
Table 16: Gastric Cancer, France, Estimated Sales of Herceptin ($m), 20102020 24
Table 17: Gastric Cancer, Germany, Estimated Sales of Herceptin ($m), 20102020 25
Table 18: Gastric Cancer, Italy , Estimated Sales of Herceptin ($m), 20102020 26
Table 19: Gastric Cancer, Spain , Estimated Sales of Herceptin ($m), 20102020 27
Table 20: Gastric Cancer, Japan , Estimated Sales of Herceptin ($m), 20112020 28

List of Chart


Figure 1: Percentage Distribution of the Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of the Top 20 Cancers 5
Figure 3:Smoking Consumption Curve, the US,1976-2006 6
Figure 4: Forecasted Global Gastric Cancer Market 7
Figure 5: Oncology,Global,Incidence(in million),20082030 8
Figure 6: Gastric Cancer, Global, Incidence(in million),20082030 8
Figure 7: Broad Classification of Gastric Cancer in the US and EU 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of NMI Gastric Cancer in The US and EU 12
Figure 11: Classification of NMI Gastric Cancer in Japan 12
Figure 12: Drug Model Diagram of Herceptin for the US and the EU 18
Figure 13: Drug Model Diagram of Herceptin for Japan 19
Figure 14: Gastric Cancer, Global , Sales Forecasts ($m) , 20102020 21
Figure 15: Gastric Cancer, The US, Sales Forecasts ($m), 2011-2020 22
Figure 16: Gastric Cancer, The UK, Estimated Sales of Herceptin ($m), 2010-2020 23
Figure 17: Gastric Cancer, France, Estimated Sales Forecast of Herceptin ($m), 2010-2020 24
Figure 18: Gastric Cancer, Germany, Estimated Sales of Herceptin ($m), 2010-2020 25
Figure 19: Gastric Cancer, Italy, Estimated Sales of Herceptin ($m), 2010-2020 26
Figure 20: Gastric Cancer, Spain, Estimated Sales of Herceptin ($m), 2010-2020 27
Figure 21: Gastric Cancer, Japan , Estimated Sales of Herceptin ($m), 2011-2020 28
Figure 22: Gastric Cancer, The US, EU5 , Japan, Sales Distribution, 2020 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *